UNSPSC 51342310: Valacyclovir hydrochloride

This classification denotes a purine antagonist and antiviral agent with the molecular formula C13H20N6O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G447S0T1VC, chemically known as l-valine, ester with 9-((2-hydroxyethoxy)methyl)guanine, monohydrochloride but generally known as valaciclovir hydrochloride, which bears US NIH Compound Identifier 60772. European Medicines Agency schedules Valaciclovir hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB15679MIG.

As of Q4 2014, VALACYCLOVIR HYDROCHLORIDE remains the US FDA Preferred Term for this commodity. Valacyclovir hydrochloride bears US NLM identifiers UMLS ID C0771309 and NCI Concept Code C29535. SMILES: CL.O(C(=O)C(N)C(C)C)CCOCN1C2[NH]C(NC(=O)C2NC1)N.

UNSPSC 51342310 Valacyclovir hydrochloride is a Commodity code that shows minimal recent state and local procurement activity directly aligned with the antiviral pharmaceutical product its name describes. The code's recent opportunities record includes two pharmaceutical and medical-supply solicitations with no direct relevance to valacyclovir hydrochloride specifically, one drug-deactivation and naloxone procurement unrelated to antiviral treatment, and one broad RFI on prescription-program architecture rather than product procurement. The mismatch between the code's nominal scope and the actual opportunities tagged to it suggests either tagging error in the underlying procurement system or that valacyclovir hydrochloride procurement at state and local level occurs too infrequently or under different codes to appear in recent postings.

The one solicitation with plausible relevance is the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802) issued by the Minnesota Department of Administration's Office of State Procurement for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, which establishes contracts for distribution through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC to state and local facilities in Minnesota and Oregon. That RFP weighted price competitiveness at 75 percent, required cGMP and Drug Supply Chain Security Act (DSCSA) compliance, and mandated at least one-year expiration dates from manufacture with six-month minimum shelf life, but does not name valacyclovir hydrochloride among the product examples. The remaining recent opportunities—Seminole County's naloxone and drug-deactivation procurement (IFB 60459723LAS, due July 26, 2023), Tampa Fire Department's medical and first-aid supplies (IFB 26P00145, due March 13, 2026, estimated $700,000 with SLBE set-aside), and Texas HHS Commission's RFI on direct-to-manufacturer prescription programs—do not address antiviral pharmaceuticals. No clear geographic concentration or repeat-buyer pattern for valacyclovir hydrochloride procurement emerges from the recent opportunities block.